Literature DB >> 25672606

The elevated preoperative neutrophil-to-lymphocyte ratio predicts poor prognosis in intrahepatic cholangiocarcinoma patients undergoing hepatectomy.

Qing Chen1, Liu-Xiao Yang, Xue-Dong Li, Dan Yin, Shi-Ming Shi, Er-Bao Chen, Lei Yu, Zheng-Jun Zhou, Shao-Lai Zhou, Ying-Hong Shi, Jia Fan, Jian Zhou, Zhi Dai.   

Abstract

A high preoperative peripheral blood neutrophil-to-lymphocyte ratio (NLR) has been reported to be a predictor of poor survival in patients with various cancers. The aim of this study was to evaluate the predictive significance of the NLR in patients undergoing hepatectomy for intrahepatic cholangiocarcinoma (ICC). From 2005 to 2011, 322 patients who underwent hepatectomy for ICC were enrolled in this retrospective study. Clinicopathological parameters, including NLR, were evaluated to identify predictors of overall and recurrence-free survival after hepatectomy. The best cutoff for NLR was 2.49, and 177 of 322 patients (54.9 %) had an NLR ≥ 2.49. The 5-year survival rate after hepatectomy was 51.1 % in patients with NLR < 2.49 and 24.8 % in those with NLR ≥ 2.49 (P = 0.0001). Univariate analyses revealed that NLR was significantly associated with recurrence-free survival (RFS) and overall survival (OS; both P < 0.05). Multivariable analyses revealed that elevated NLR independently predicted poorer OS (P = 0.003, hazard ratio [HR] = 1.600). In summary, our results indicate that elevated NLR is a promising independent predictor of poor survival after hepatectomy in patients with ICC.

Entities:  

Mesh:

Year:  2015        PMID: 25672606     DOI: 10.1007/s13277-015-3188-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  54 in total

1.  Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma.

Authors:  Karim J Halazun; Mark A Hardy; Abbas A Rana; David C Woodland; Elijah J Luyten; Suhari Mahadev; Piotr Witkowski; Abbey B Siegel; Robert S Brown; Jean C Emond
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

2.  A western surgical experience of peripheral cholangiocarcinoma.

Authors:  S V Berdah; J R Delpero; S Garcia; J Hardwigsen; Y P Le Treut
Journal:  Br J Surg       Date:  1996-11       Impact factor: 6.939

3.  Association of neutrophil-lymphocyte ratio with impaired aortic elasticity in newly diagnosed and never-treated hypertensive patients.

Authors:  Çağr Yayla; Uğur Canpolat; Ahmet Akyel; Kadriye Gayretl Yayla; Mehmet K Akboğa; Azmi Eyiol; Eser Açkgöz; Selçuk Özkan; Rdvan Yalçn; Nuri B Boyac
Journal:  Blood Press Monit       Date:  2015-06       Impact factor: 1.444

4.  Role of IL-17A in neutrophil recruitment and hepatic injury after warm ischemia-reperfusion mice.

Authors:  Hiroshi Kono; Hideki Fujii; Masahito Ogiku; Naohiro Hosomura; Hidetake Amemiya; Masato Tsuchiya; Michio Hara
Journal:  J Immunol       Date:  2011-09-26       Impact factor: 5.422

5.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

6.  A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI).

Authors:  David J Pinato; Justin Stebbing; Mitsuru Ishizuka; Shahid A Khan; Harpreet S Wasan; Bernard V North; Keiichi Kubota; Rohini Sharma
Journal:  J Hepatol       Date:  2012-06-23       Impact factor: 25.083

7.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

8.  Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells.

Authors:  Eva V Acosta-Rodriguez; Laura Rivino; Jens Geginat; David Jarrossay; Marco Gattorno; Antonio Lanzavecchia; Federica Sallusto; Giorgio Napolitani
Journal:  Nat Immunol       Date:  2007-05-07       Impact factor: 25.606

9.  Systemic inflammatory response predicts survival following curative resection of colorectal cancer.

Authors:  D C McMillan; K Canna; C S McArdle
Journal:  Br J Surg       Date:  2003-02       Impact factor: 6.939

10.  A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer.

Authors:  M J Proctor; D C McMillan; D S Morrison; C D Fletcher; P G Horgan; S J Clarke
Journal:  Br J Cancer       Date:  2012-07-24       Impact factor: 7.640

View more
  29 in total

1.  Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.

Authors:  Wei-wei Zhang; Ke-jun Liu; Guo-lin Hu; Wei-jiang Liang
Journal:  Tumour Biol       Date:  2015-06-11

2.  Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium.

Authors:  Eliza W Beal; Lai Wei; Cecilia G Ethun; Sylvester M Black; Mary Dillhoff; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Timothy M Pawlik; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt
Journal:  HPB (Oxford)       Date:  2016-09-24       Impact factor: 3.647

3.  The diagnostic and prognostic value of MRP8/MRP14 in intrahepatic cholangiocarcinoma.

Authors:  Guang-Zhi Jin; Wei Dong; Hui Dong; Hua Yu; Jia Chen; Wen-Long Yu; Ai-Jun Li; Wen-Ming Cong; Meng-Chao Wu
Journal:  Oncotarget       Date:  2015-11-17

4.  Prognostic nutritional index serves as a predictive marker of survival and associates with systemic inflammatory response in metastatic intrahepatic cholangiocarcinoma.

Authors:  Chenyue Zhang; Haiyong Wang; Zhouyu Ning; Litao Xu; Liping Zhuang; Peng Wang; Zhiqiang Meng
Journal:  Onco Targets Ther       Date:  2016-10-19       Impact factor: 4.147

5.  The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma.

Authors:  Jie Wang; Shengzi Wang; Xinmao Song; Wenjiao Zeng; Shuyi Wang; Fu Chen; Hao Ding
Journal:  Onco Targets Ther       Date:  2016-11-21       Impact factor: 4.147

6.  The C-reactive Protein/Albumin Ratio Is an independent Prognostic Factor for Overall Survival in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.

Authors:  Chang-Juan Tao; Yuan-Yuan Chen; Feng Jiang; Xing-Lai Feng; Qi-Feng Jin; Ting Jin; Yong-Feng Piao; Xiao-Zhong Chen
Journal:  J Cancer       Date:  2016-10-11       Impact factor: 4.207

7.  Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma.

Authors:  Guohe Lin; Yongcheng Liu; Shuhong Li; Yize Mao; Jun Wang; Zeyu Shuang; Jianlin Chen; Shengping Li
Journal:  Oncotarget       Date:  2016-08-09

Review 8.  Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Colorectal Liver Metastasis: A Systematic Review and Meta-Analysis.

Authors:  Haowen Tang; Bingmin Li; Aiqun Zhang; Wenping Lu; Canhong Xiang; Jiahong Dong
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

Review 9.  Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic Outcomes of Cholangiocarcinoma: A Meta-analysis.

Authors:  De-Wen Tan; Yan Fu; Qi Su; Ming-Jun Guan; Po Kong; Sheng-Qiang Wang; He-Ling Wang
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

10.  The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis.

Authors:  Ross D Dolan; Jason Lim; Stephen T McSorley; Paul G Horgan; Donald C McMillan
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.